Treatment of allergies
OwnerShoshana Levy, Rosemarie H. Dekruyff +2inventors
InventorsShoshana Levy, Rosemarie H. Dekruyff, Dale Teiji Umetsu, Holden Maecker
Life of this patent
Estimating the term…
Abstract
Allergic and other immune disorders associated with antigen specific T cells are treated by administering a vaccine comprising sequences of a fusion protein of IL-18 and antigen. The methods are particularly useful in decreasing an established antigen specific IgE immune response. Conditions of particular interest include asthma, allergic rhinitis, IgE-mediated anaphylactic reactions to insect stings, and other allergic conditions.
Claims11
A method of enhancing a Th1 T cell mediated immune response, the method comprising:
- administering an effective dose of a fusion protein of IL-18 and an antigen associated with said response;
- wherein the response of said Th1 T cell is enhanced.
A method of diminishing a Th2 T cell mediated antigen-specific allergic response, the method comprising:
- administering an effective dose of a DNA construct encoding a fusion protein of IL-18 and an antigen associated with said allergic response for a period of time sufficient to diminish said antigen-specific allergic response.
A method of treating asthma associated allergies, the method comprising:
- administering an effective dose of a DNA construct encoding a fusion protein of IL-18 and an antigen associated with said asthma for a period of time sufficient to diminish said asthma associated allergies.
A pharmaceutical composition for the treatment of allergies, comprising:
- a DNA construct encoding a fusion protein comprising an allergy associated antigen and interleukin 18;
- and
- a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.